卡泊西单抗应如何用于治疗免疫性血栓性血小板减少性紫癜？ - Suppr

Suppr

超能文献

How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?

作者信息

Zheng Lucy, Zheng X Long

机构信息

Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS, USA.

出版信息

Ann Blood. 2023 Jun 30;8. doi: 10.21037/aob-21-87. Epub 2022 Apr 1.

DOI:10.21037/aob-21-87

PMID:37200543

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10187608/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea94/10187608/df33c9a2e3cb/nihms-1837759-f0001.jpg

相似文献

How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?卡泊西单抗应如何用于治疗免疫性血栓性血小板减少性紫癜？

Ann Blood. 2023 Jun 30;8. doi: 10.21037/aob-21-87. Epub 2022 Apr 1.

Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience.卡普拉珠单抗治疗免疫性血栓性血小板减少性紫癜：加拿大单中心真实世界经验。

Platelets. 2023 Dec;34(1):2157807. doi: 10.1080/09537104.2022.2157807.

Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry.卡泊单抗用于免疫性血栓性血小板减少性紫癜：米兰血栓性血小板减少性紫癜登记研究

Res Pract Thromb Haemost. 2023 Aug 26;7(6):102185. doi: 10.1016/j.rpth.2023.102185. eCollection 2023 Aug.

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.卡普雷珠单抗可降低获得性血栓性血小板减少性紫癜患者的主要血栓栓塞事件、恶化事件和死亡的发生频率。

J Thromb Haemost. 2017 Jul;15(7):1448-1452. doi: 10.1111/jth.13716. Epub 2017 Jun 5.

Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study.接受一线治疗与延迟使用卡普西单抗治疗免疫性血栓性血小板减少性紫癜患者的结局和成本：一项美国医院数据库研究。

Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241241525. doi: 10.1177/10760296241241525.

Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura.卡普拉珠单抗作为一线治疗药物对免疫性血栓性血小板减少性紫癜治疗结局的影响。

J Thromb Haemost. 2023 Mar;21(3):559-572. doi: 10.1016/j.jtha.2022.11.010. Epub 2022 Dec 22.

Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons.我们是否应该考虑将 caplacizumab 作为急性血栓性血小板减少性紫癜的常规治疗方法？专家对其利弊的看法。

Expert Rev Hematol. 2024 Jan-Mar;17(1-3):9-25. doi: 10.1080/17474086.2024.2318347. Epub 2024 Feb 20.

Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura.卡泊单抗隔日给药治疗免疫性血栓性血小板减少性紫癜。

J Thromb Haemost. 2022 Apr;20(4):951-960. doi: 10.1111/jth.15637. Epub 2022 Jan 23.

Von Willebrand factor assays in patients with acquired immune thrombotic thrombocytopenia purpura treated with caplacizumab.在接受卡普拉西珠单抗治疗的获得性免疫性血栓性血小板减少性紫癜患者中进行 von Willebrand 因子检测。

Br J Haematol. 2022 May;197(3):349-358. doi: 10.1111/bjh.18080. Epub 2022 Mar 8.

Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura?卡普雷珠单抗：在妊娠相关免疫性血栓性血小板减少性紫癜中也是改变游戏规则的药物？

Br J Haematol. 2023 Aug;202(4):725-727. doi: 10.1111/bjh.18915. Epub 2023 Jun 8.

引用本文的文献

Animal models for thrombotic thrombocytopenic purpura: a narrative review.血栓性血小板减少性紫癜的动物模型：一项叙述性综述。

Ann Blood. 2023 Sep 30;8. doi: 10.21037/aob-22-18. Epub 2022 Nov 16.

Introductory comments about the special series of thrombotic microangiopathy.关于血栓性微血管病专题系列的引言性评论。

Ann Blood. 2024 Jun 30;9. doi: 10.21037/aob-24-6. Epub 2024 Apr 1.

Pathological Mechanisms and Novel Testing Methods in Thrombotic Thrombocytopenic Purpura.血栓性血小板减少性紫癜的病理机制及新型检测方法

Biomedicines. 2024 Mar 11;12(3):621. doi: 10.3390/biomedicines12030621.

本文引用的文献

High-resolution structure of the vWF A1 domain in complex with caplacizumab, the first nanobody-based medicine for treating acquired TTP.与 caplacizumab 复合物的 vWF A1 结构域的高分辨率结构，该药物是首个用于治疗获得性 TTP 的基于纳米体的药物。

Biochem Biophys Res Commun. 2021 Aug 27;567:49-55. doi: 10.1016/j.bbrc.2021.06.030. Epub 2021 Jun 16.

The standard of care for immune thrombotic thrombocytopenic purpura today.目前免疫性血栓性血小板减少性紫癜的治疗标准。

J Thromb Haemost. 2021 Aug;19(8):1864-1871. doi: 10.1111/jth.15406. Epub 2021 Jun 30.

Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis.卡普芦单抗可预防获得性血栓性血小板减少性紫癜的耐药和死亡：综合分析。

Blood Adv. 2021 Apr 27;5(8):2137-2141. doi: 10.1182/bloodadvances.2020001834.

Counting the cost of caplacizumab.计算卡帕单抗的成本。

Blood. 2021 Feb 18;137(7):871-872. doi: 10.1182/blood.2020009250.

Redefining outcomes in immune TTP: an international working group consensus report.重新定义免疫性血栓性血小板减少性紫癜的结局：国际工作组共识报告。

Blood. 2021 Apr 8;137(14):1855-1861. doi: 10.1182/blood.2020009150.

Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.卡泊西单抗治疗获得性血栓性血小板减少性紫癜的成本效益

Blood. 2021 Feb 18;137(7):969-976. doi: 10.1182/blood.2020006052.

Plasma levels of S100A8/A9, histone/DNA complexes, and cell-free DNA predict adverse outcomes of immune thrombotic thrombocytopenic purpura.血浆 S100A8/A9、组蛋白/DNA 复合物和游离细胞 DNA 水平预测免疫性血栓性血小板减少性紫癜的不良结局。

J Thromb Haemost. 2021 Feb;19(2):370-379. doi: 10.1111/jth.15176. Epub 2021 Jan 3.

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.卡泊单抗、免疫抑制和血浆置换联合治疗方案可预防免疫介导的血栓性血小板减少性紫癜的不良结局。

Blood. 2021 Feb 11;137(6):733-742. doi: 10.1182/blood.2020008021.

ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura.ISTH 血栓性血小板减少性紫癜诊断指南。

J Thromb Haemost. 2020 Oct;18(10):2486-2495. doi: 10.1111/jth.15006. Epub 2020 Sep 11.

ISTH guidelines for treatment of thrombotic thrombocytopenic purpura.国际血栓与止血学会（ISTH）血栓性血小板减少性紫癜治疗指南。

J Thromb Haemost. 2020 Oct;18(10):2496-2502. doi: 10.1111/jth.15010. Epub 2020 Sep 11.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验